Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obexelimab in IgG4-Related Disease
NCT02725476Phase 2Completed
- Sponsor
- Xencor
- Start
- Mar 2016
- Primary completion
- Dec 2017
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obexelimab in IgG4-related disease (IgG4-RD), sponsored by Xencor. Started Mar 2016; status: completed.
02
Drugs
obexelimab
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT02725476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02725476.